A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats.
The synthetic chalcone derivative 1-(2,4-dichlorophenyl)-3-(3-(6,7-dimethoxy-2-chloroquinolinyl))-2-propen-1-one (ClDQ) was evaluated for its anti-inflammatory, analgesic and immunomodulatory efficacy in-vitro and in-vivo. ClDQ concentration-dependently inhibited the production of nitric oxide (NO) (IC50 4.3 microM) and prostaglandin E(2) (PGE(2)) (IC50 1.8 microM) in RAW 264.7 macrophages stimulated with lipopolysaccharide. Human mononuclear cell proliferation was significantly inhibited by 10 microM ClDQ. Oral administration of ClDQ (10-30 mg kg(-1)) in the 24-h zymosan-stimulated mouse air-pouch model produced a dose-dependent reduction of cell migration as well as NO and PGE(2) levels in exudates. ClDQ (20 mg kg(-1), p.o.) inhibited ear swelling and leucocyte infiltration in the delayed-type hypersensitivity response to 2,4-dinitrofluorobenzene in mice. In the rat adjuvant-arthritis model, this compound reduced joint inflammation as well as PGE(2) and cytokine levels. In addition, ClDQ displayed analgesic effects in the phenylbenzoquinone-induced abdominal constriction model in mice and in the late phase of the nociceptive response to formalin. Our findings indicated the potential interest of ClDQ in the modulation of some immune and inflammatory conditions.
De León
E J
EJ
Department of Pharmacology, University of Valencia, Faculty of Pharmacy, Burjassot, Spain.
Alcaraz
M J
MJ
Dominguez
J N
JN
Charris
J
J
Terencio
M C
MC
D000007:Abdominal Injuries / Q000139:chemically induced / Q000517:prevention & control; D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000139:chemically induced / Q000276:immunology; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology; D002460:Cell Line; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004139:Dinitrofluorobenzene; D015232:Dinoprostone / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000276:immunology / Q000517:prevention & control; D005260:Female; D005557:Formaldehyde; D054501:Group II Phospholipases A2; D054513:Group IV Phospholipases A2; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008264:Macrophages / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology; D009573:Nitrites / Q000378:metabolism; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control; D010147:Pain Measurement / Q000379:methods; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D011724:Pyridazines / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D013929:Thromboxane B2 / Q000378:metabolism; D015054:Zymosan
D008070:Lipopolysaccharides; D009573:Nitrites; D011724:Pyridazines; C510844:p-methoxy-dichloro-pyridazone; D005557:Formaldehyde; D013929:Thromboxane B2; D015054:Zymosan; D004139:Dinitrofluorobenzene; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054513:Group IV Phospholipases A2; D015232:Dinoprostone